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Abstract 
 
Aims: To estimate the association of smoking status with rates of i) infection, ii) hospitalisation, iii) 
disease severity, and iv) mortality from SARS-CoV-2/COVID-19 disease.  
 
Design: Living rapid review of observational and experimental studies with random-effects 
hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE 
and medRxiv. 
 
Setting: Community or hospital. No restrictions on location. 
 
Participants: Adults who received a SARS-CoV-2 test or a COVID-19 diagnosis. 
 
Measurements: Outcomes were SARS-CoV-2 infection, hospitalisation, disease severity and 
mortality stratified by smoking status. Study quality was assessed (i.e. ‘good’, ‘fair’ and ‘poor’). 
 
Findings: Version 7 (searches up to 25 August 2020) included 233 studies with 32 ‘good’ and ‘fair’ 
quality studies included in meta-analyses. Fifty-seven studies (24.5%) reported current, former and 
never smoking status. Recorded smoking prevalence among people with COVID-19 was generally 
lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-
CoV-2 infection (RR=0.74, 95% Credible Interval (CrI) = 0.58-0.93, τ  .41). Data for former smokers 
were inconclusive (RR=1.05, 95% CrI = 0.95-1.17, τ  .17) but favoured there being no important 
association (21% probability of RR . ). Former compared with never smokers were at somewhat 
increased risk of hospitalisation (RR=1.20, CrI = 1.03- . , τ  . ), greater disease severity 
(RR=1.52, CrI = 1.13- . , τ  . ), and mortality (RR . ,  CrI  . - . , τ  . ). Data for 
current smokers were inconclusive (RR=1.06, CrI = 0.82- . , τ  . ; RR . , CrI  . - . , τ  
0.34; RR=1.22, 95% CrI = 0.78- . , τ  .  respectively) but favoured there being no important 
associations with hospitalisation and mortality (35% and 70% probability of RR . , respectively) 
and a small but important association with disease severity (79% probability of RR . ).  
 
Conclusions: Compared with never smokers, current smokers appear to be at reduced risk of SARS-
CoV-2 infection while former smokers appear to be at increased risk of hospitalisation, increased 
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disease severity and mortality from COVID-19. However, it is uncertain whether these associations 
are causal. 
Introduction 
 
COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Large age and gender differences 
in case severity and mortality have been observed in the ongoing COVID-19 pandemic1; however, 
these differences are currently unexplained. SARS-CoV-2 enters epithelial cells through the 
angiotensin-converting enzyme 2 (ACE-2) receptor2. Some evidence suggests that gene expression 
and subsequent receptor levels are elevated in the airway and oral epithelium of current smokers3,4, 
thus putting smokers at higher risk of contracting SARS-CoV-2. Other studies, however, suggest that 
nicotine downregulates the ACE-2 receptor5. These uncertainties notwithstanding, both former and 
current smoking is known to increase the risk of respiratory viral6,7 and bacterial8,9 infections and is 
associated with worse outcomes once infected. Cigarette smoke reduces the respiratory immune 
defence through peri-bronchiolar inflammation and fibrosis, impaired mucociliary clearance and 
disruption of the respiratory epithelium10. There is also reason to believe that behavioural factors 
(e.g. regular hand-to-mouth movements) involved in smoking may increase SARS-CoV-2 infection 
and transmission in current smokers. However, early data from the COVID-19 pandemic have not 
provided clear evidence for a negative impact of current or former smoking on SARS-CoV-2 infection 
or COVID-19 disease outcomes, such as hospitalisation or mortality11. It has also been hypothesised 
that nicotine might protect against a hyper-inflammatory response to SARS-CoV-2 infection, which 
may lead to adverse outcomes in patients with COVID-19 disease12. 
 
There are several reviews that fall within the scope of smoking and COVID-1911,13–18. We aimed to 
produce a rapid synthesis of available evidence pertaining to the rates of infection, hospitalisation, 
disease severity and mortality from SARS-CoV-2/COVID-19 stratified by smoking status. Given the 
increasing availability of data on this topic, this is a living review with regular updates. As evidence 
accumulates, the review will be expanded to include studies reporting COVID-19 outcomes by 
alternative nicotine use (e.g., nicotine replacement therapy or e-cigarettes). 
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Methods 
 
Study design 
 
This is a living evidence review which is updated as new evidence becomes available19. We adopted 
recommended best practice for rapid evidence reviews, which involved limiting the search to main 
databases and having one reviewer extract the data and another verify20. This study was not pre-
registered but evolved from a report written for a UK medical society21. The most recent (and all 
future) version(s) of this living review is available here (https://www.qeios.com/read/latest-
UJR2AW). A completed Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) checklist is included in Supplementary file 1. 
 
Eligibility criteria 
 
Studies were included if they: 
 
1) Were primary research studies using experimental (e.g. randomised controlled trial), quasi-
experimental (e.g. pre- and post-test) or observational (e.g. case-control, retrospective 
cohort, prospective cohort) study designs; 
2) Included adults aged 16+ years; 
3) Recorded as outcome i) results of a SARS-CoV-2 diagnostic test (including antibody assays), 
ii) clinical diagnosis of COVID-19, iii) hospitalisation with COVID-19, iv) severity of COVID-19 
disease in those hospitalised or v) mortality from COVID-19;  
4) Reported any of the outcomes of interest by self-reported or biochemically verified smoking 
status (e.g. current smoker, former smoker, never smoker) or current vaping and nicotine 
replacement therapy (NRT) use; 
5) Were available in English; 
6) Were published in a peer-reviewed journal, as a pre-print or a public health report by 
reputable agents (e.g. governments, scientific societies). 
 
Search strategy 
 
The following terms were searched for in Ovid MEDLINE (2019-search date) as free text or Medical 
Subject Headings: 
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1. Tobacco Smoking/ or Smoking Cessation/ or Water Pipe Smoking/ or Smoking/ or Smoking 
Pipes/ or Cigar Smoking/ or Smoking Prevention/ or Cigarette Smoking/ or smoking.mp. or 
Pipe Smoking/ or Smoking, Non-Tobacco Products/ or Smoking Water Pipes/ 
2. Nicotine/ or nicotine.mp. or Electronic Nicotine Delivery Systems/ or Nicotine Chewing 
Gum/ 
3. vaping.mp. or Vaping/ 
4. 1 or 2 or 3 
5. Coronavirus/ or Severe Acute Respiratory Syndrome/ or Coronavirus Infections/ or covid.mp. 
6. 4 and 5 
 
The following terms were searched for in titles, abstracts and full texts in medRxiv (no time 
limitations): 
 
1. covid (this term captures both covid and SARS-CoV-2) AND smoking 
2. covid AND nicotine 
3. covid AND vaping 
 
Additional articles/reports of interest were identified through mailing lists, Twitter, the International 
Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) and the US Centers for 
Disease Control and Prevention (CDC). Where updated versions of pre-prints or public health 
reports were available, old versions were superseded. 
 
Selection of studies 
 
One reviewer screened titles, abstracts and full texts against the inclusion criteria. 
 
Data extraction 
 
Data were extracted by one reviewer and verified (i.e. independently checked against pre-prints and 
published reports) by another on i) author (year); ii) date published; iii) country; iv) study design; v) 
study setting; vi) sample size; vii) sex; viii) age; ix) smoking status (e.g. current, former, never, not 
stated, missing); x) use of alternative nicotine products; xi) SARS-CoV-2 testing; xii) SARS-CoV-2 
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infection; xiii) diagnosis of COVID-19; xiv) hospitalisation with COVID-19; xv) disease severity in those 
hospitalised with COVID-19; and xvi) mortality. 
 
Quality appraisal 
 
The quality of included studies was assessed to determine suitability for inclusion in meta-analyses. 
Studies were judged as ‘good’ quality if they: i) had <20% missing data on smoking status and used a 
reliable self-report measure that distinguished between current, former and never smoking status; 
AND ii) used biochemical verification of smoking status and reported results from adjusted analyses; 
OR reported data from a representative/random sample. Studies were rated as ‘fair’ if they fulfilled 
only criterion i) and were otherwise rated as ‘poor’. The quality appraisal was conducted by one 
reviewer and verified by a second.  
 
Evidence synthesis 
 
A narrative synthesis was conducted. Data from ‘good’ and ‘fair’ quality studies were pooled in R 
v.3.6.322. In a living review where new data are regularly added to the analyses, it may be more 
appropriate to use a Bayesian (as opposed to frequentist) approach where prior knowledge is used 
in combination with new data to estimate a posterior risk distribution. A Bayesian approach 
mitigates against the issue of performing multiple statistical tests, which can inflate family-wise 
error. A series of random-effects hierarchical Bayesian meta-analyses were performed with the 
brms23 package to estimate the relative risk for each comparison with accompanying 95% credible 
intervals (CrIs). We first defined prior distributions for the true pooled effect size (µ) and the 
between-study heterogeneity (τ), with µ specified as a normal distribution with a mean equal to the 
derived point estimate from each comparison of interest in the immediately preceding version of 
this living review24, and τ specified as a half-Cauchy distribution with a mean of 0 and standard 
deviation of 1. The half-Cauchy distribution was selected to reflect prior knowledge that high levels 
of between-study heterogeneity are more likely than lower levels. Markov Chain Monte Carlo 
methods (20,000 burn-ins followed by 80,000 iterations) were then used to generate a risk 
distribution for each study, in addition to a pooled effect for the posterior risk distribution. We 
report forest plots with the pooled effect for the posterior risk distribution displayed as the median 
relative risk with an accompanying 95% CrIs. We used the empirical cumulative distribution function 
(ECDF) to estimate the probability of there being a 10% reduction or 10% increase in relative risk 
(RR) (i.e. RR .  or RR . ). Due to a lack of indication as to what constitutes a clinically or 
epidemiologically meaningful effect (e.g. with regards to onward disease transmission or 
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requirements for intensive care beds), we deemed a 10% change in risk as small but important. 
Where data were inconclusive (as indicated by CrIs crossing RR = 1.0), to disambiguate whether data 
favoured no effect or there being a small but important association, we estimated whether there 
was  probability of RR .  or RR . . 
Two sensitivity analyses were performed. First, a minimally informative prior for µ was specified as a 
normal distribution with a mean of 0 and standard deviation of 1 and τ as described above. Second, 
an informative prior as described above for µ was used with τ specified as a half-Cauchy distribution 
with a mean of 0.3 and standard deviation of 1 to reflect greater between-study heterogeneity. 
To aid in the visualisation of smoking prevalence in the included studies, 95% bootstrap percentile 
confidence intervals were calculated for each study. We performed 1,000 bootstrap replications, 
with the 2.5th and 97.5th percentiles of the empirical distribution forming the 95% bootstrap 
percentile confidence intervals25 (CIs). It should be noted that prevalence estimates in the included 
studies were not adjusted for age, sex, socioeconomic position, or region within countries. 
Results 
 
In the current review version (v7) with searches up to 25 August 2020, a total of 347 new records 
were identified, with 233 studies included in a narrative synthesis and 32 studies included in meta-
analyses (see Figure 1). 
 
Study characteristics 
 
Characteristics of included studies are presented in Table 1. Studies were conducted across 33 
countries. Sixty-two studies were conducted in the US, 53 in China, 26 in the UK, 13 in Spain, 12 in 
Mexico, 11 in France, seven in Italy, six across multiple international sites, four in Brazil and Iran, 
three in Israel and Turkey, two in Bangladesh, Chile, Denmark, Finland, India, Japan and Qatar and 
one from 15 further countries (see Supplementary figure S1). The majority of studies used 
observational designs (see Supplementary table S1). One-hundred-and-fifty-five studies were 
conducted in hospital settings, 62 studies included a community component in addition to 
hospitalised patients and 14 studies were conducted exclusively in the community, one in a 
quarantine centre and one did not state the study setting. Studies had a median of 404 (interquartile 
range = 115-1,631) participants. The majority of studies (93.5%) used reverse transcriptase 
polymerase chain reaction (RT-PCR) for confirmation of SARS-CoV-2 infection, 2.6% used an antibody 
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test to confirm prior infection, and 3.9% further studies relied on a combination of RT-PCR and 
clinical diagnosis (see Supplementary table S1). 
 
Smoking status 
 
Categorisation of smoking status was heterogeneous (see Table 1). One-hundred-and-forty-five 
studies collected data on smoking status through routine electronic health records (EHRs), 59 studies 
used a bespoke case report form for COVID-19 and 29 studies did not state the source for 
information on smoking status. None of the studies verified smoking status biochemically. Notably, 
only 57 (24.4%) studies reported current, former and never smoking status (see Supplementary table 
S2a), with a further 17 studies reporting ever and never smoking status (see Supplementary table 
S2b). The remaining 159 studies reported current, current/former or current and former smoking 
status but did not explicitly state whether remaining participants were never smokers or if data were 
missing on smoking status (see Supplementary table S2c). Seventy-eight studies explicitly reported 
the proportion with missing data on smoking status, which ranged from 0.08% to 96.4%.  
 
Use of alternative nicotine products 
 
Five studies recorded the use of alternative nicotine products in current and/or former smokers but 
did not report COVID-19 outcomes stratified by nicotine use26–30. 
 
Quality appraisal 
 
One study was performed in a random, representative population sample and was rated as ‘good’ 
quality. Forty-six studies were rated as ‘fair’ quality. The remaining 186 studies were rated as ‘poor’ 
quality (see Table 1). 
Smoking prevalence by country 
 
Unadjusted smoking prevalence compared with overall estimates for national adult smoking 
prevalence split by country and study setting is presented in Figure 2a and 2b. Lower than expected 
current smoking prevalence was generally observed. Former smoking prevalence was more similar 
to expected prevalence when reported. National smoking prevalence estimates used for comparison 
are presented in Supplementary table 3. 
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SARS-CoV-2 testing by smoking status 
 
Three studies provided data on access to SARS-CoV-2 diagnostic testing for those meeting local 
testing criteria by smoking status. In a cohort study of US military veterans aged 54-7531, current 
smokers were more likely to receive a test: 42.3% (1,603/3,789) of the sample were current smokers 
compared with 23.8% of all veterans aged 50+ years using any tobacco product between 2010-
201532. In the UK Biobank cohort33, former (RR = 1.29, 95% CI = 1.14-1.45, p < .001) and current (RR = 
1.44, 95% CI = 1.20-1.71, p < .001) compared with never smokers were more likely to receive a test 
in a multivariable analysis. In an Australian rapid assessment screening clinic for COVID-1934, 9.4% 
(397/4,226) of the self-referred sample (subsequently assessed by a healthcare professional to 
decide on testing) were current smokers. Current compared with former or never smokers were less 
likely to require a test (RR = 0.93, 95% CI = 0.86-1.0, p = 0.045). 
 
SARS-CoV-2 infection by smoking status 
 
Forty-five studies provided data on SARS-CoV-2 infection for people meeting local testing criteria by 
smoking status (see Table 2). Meta-analyses were performed for one ‘good’ and 16 ‘fair’ quality 
studies (see Figure 4 and 5). Current smokers were at reduced risk of testing positive for SARS-CoV-2 
compared with never smokers (RR = 0.74, 95% CrI = 0.58-0.93, τ  .41, 95% CI = 0.24-0.64). The 
probability of current smokers being at reduced risk of infection compared with never smokers (RR 
.9) was 95%. Former compared with never smokers were at increased risk of testing positive, but 
data were inconclusive (RR = 1.05, 95% CrI = 0.95-1.17, τ  .17, 95% CI = 0.10-0.26) and favoured 
there being no important association. The probability of former smokers being at increased risk of 
infection (RR . ) compared with never smokers was 21%. Results were materially unchanged in 
the two sensitivity analyses (see Supplementary figure S2). 
 
Hospitalisation for COVID-19 by smoking status 
 
Twenty-nine studies examined hospitalisation for COVID-19 disease stratified by smoking status (see 
Table 3). Meta-analyses were performed for eight ‘fair’ quality studies (see Figure 6 and 7). Current 
(RR = 1.06, CrI = 0.82-1.35, τ  .27, 95% CI = 0.08-0.55) and former (RR = 1.20, CrI = 1.03-1.44, τ  
0.17, 95% CI = 0.06-0.37) compared with never smokers were at increased risk of hospitalisation 
with COVID-19, but data for current smokers were inconclusive and favoured there being no 
important association. The probability of current and former smokers being at increased risk of 
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hospitalisation compared with never smokers was 35% and 89%, respectively. Results were 
materially unchanged in two sensitivity analyses (see Supplementary figure S3). 
 
Disease severity by smoking status 
 
Sixty studies reported disease severity in hospitalised patients stratified by smoking status (see Table 
4). Severe (as opposed to non-severe) disease was broadly defined as requiring intensive treatment 
unit (ITU) admission, requiring oxygen as a hospital inpatient or in-hospital death. Meta-analyses 
were performed for eight ‘fair’ quality studies (see Figure 8 and 9). Current (RR = 1.25, CrI = 0.85-
1.93, τ  .34, 95% CI = 0.01-0.86) and former (RR = 1.52, CrI = 1.13-2.07, τ  .29, 95% CI = 0.47-
0.66) compared with never smokers were at increased risk of greater disease severity; data for 
current smokers were inconclusive but favoured there being a small but important association. The 
probability of current and former smokers having increased risk of greater disease severity 
compared with never smokers was 79% and 98%, respectively. Results were materially unchanged in 
two sensitivity analyses (see Supplementary figure S4). 
 
Mortality by smoking status 
 
Fifty studies reported mortality from COVID-19 by smoking status (see Table 5), with nine ‘fair’ 
quality studies included in meta-analyses (see Figure 10 and 11). Current (RR = 1.22, 95% CrI = 0.78-
1.94, τ  .49, 95% CI = 0.16-0.99) and former (RR = 1.39, 95% CrI = 1.09-1.87, τ  .27, 95% CI = 0.05-
0.58) compared with never smokers were at increased risk of in-hospital mortality from COVID-19. 
Data for current smokers were inconclusive but favoured there being no important association. The 
probability of current and former smokers being at greater risk of in-hospital mortality compared 
with never smokers was 70% and 97%, respectively. Results were materially unchanged in two 
sensitivity analyses (see Supplementary figure S5). 
 
 
Discussion 
 
This living rapid review found uncertainty in the majority of 233 studies arising from the recording of 
smoking status. Notwithstanding these uncertainties, compared with overall adult national 
prevalence estimates, recorded current smoking rates in most countries were lower than expected. 
In a subset of better of quality studies (n = 17), current smokers had a reduced risk of testing positive 
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for SARS-CoV-2 but appeared more likely to present for testing and/or receive a test. Data for 
current smokers on the risk of hospitalisation, disease severity and mortality were inconclusive, but 
favoured there being no important associations with hospitalisation and mortality and a small but 
important increase in the risk of severe disease. Former smokers were at increased risk of 
hospitalisation, disease severity and mortality compared with never smokers. 
 
Issues complicating interpretation 
 
Interpretation of results from studies conducted during the first phase of the SARS-CoV-2 pandemic 
is complicated by several factors (see Figure 12):  
1) Exposure to SARS-CoV-2 is heterogeneous with different subgroups at heightened risk of 
infection at different stages of the pandemic. This will likely introduce bias in studies assessing the 
rate of infection by smoking status conducted early on.  
2) Current and former smokers may be more likely to meet local criteria for community 
testing due to increased prevalence of symptoms consistent with SARS-CoV-2 infection, such as 
cough, increased sputum production or altered sense of smell or taste35. Evidence from a small 
number of studies indicates that current smokers may be more likely to present for testing, hence 
increasing the denominator in comparisons with never smokers and potentially inflating the rate of 
negative tests in current smokers. Infection positivity rates estimated among random samples will be 
more informative than currently available data. We identified one population study conducted in 
Hungary reporting on seroprevalence and smoking status36; however, the response rate was fairly 
low at 58.8% and the current smoking rate was 10 percentage points below national prevalence 
estimates, thus questioning the representativeness of the final sample. Smoking status is being 
collected in at least two large representative infection and antibody surveys in the UK37,38.  
3) Testing for acute infection requires swabbing of the mucosal epithelium, which may be 
disrupted in current smokers, potentially altering the sensitivity of assays39.  
4) Diagnostic criteria for SARS-CoV-2 infection and COVID-19 have changed during the 
course of the pandemic40. It was not possible to extract details on the specific RT-PCR technique or 
platforms used across the included studies due to reporting gaps. Different platforms have varying 
sensitivity and specificity to detect SARS-CoV-2 infection. 
5) Most included studies relied on EHRs as the source of information on smoking status. 
Research shows large discrepancies between EHRs and actual behaviour41. Known failings of EHRs 
include implausible longitudinal changes, such as former smokers being recorded as never smokers 
at subsequent hospital visits41. Misreporting on the part of the patient (perhaps due to perceived 
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stigmatisation) has also been observed, with biochemical measures showing higher rates of smoking 
compared with self-report in hospitalised patients in the US42. It is hence possible that under-
reporting of current and former smoking status in hospitals occurred across the included studies.  
6) Individuals with severe COVID-19 symptoms may have stopped smoking immediately 
before admission to hospital and may therefore not have been recorded as current smokers (i.e. 
reverse causality).  
7) Smokers with COVID-19 may be less likely to receive a SARS-CoV-2 test or present to 
hospital due to lack of access to healthcare and may be more likely to die in the community from 
sudden complications (i.e. self-selection bias) and thus not be recorded.  
8) If there is a protective effect of nicotine on COVID-19 disease outcomes, abrupt nicotine 
withdrawal upon hospitalisation may lead to worse outcomes12.  
9) During periods of heightened demand of limited healthcare resources, current and former 
smokers with extensive comorbidities may have reduced priority for intensive care admission, thus 
leading to higher in-hospital mortality.  
10) Given lack of knowledge of the disease progression and long-term outcomes of COVID-
19, it is unclear whether studies conducted thus far in the pandemic have monitored patients for a 
sufficient time period to report complete survival outcomes or whether they are subject to early 
censoring. 
11) Reasons for hospitalisation vary by country and time in the pandemic. For example, early 
cases may have been hospitalised for isolation and quarantine reasons and not due to medical 
necessity. It is plausible this may have skewed early data towards less severe cases. In addition, the 
observed association between former smoking and greater disease severity may be explained by 
collider bias43, where conditioning on a collider (e.g. testing or hospitalisation) by design or analysis 
may introduce a spurious association between current or former smoking (a potential cause of 
testing or hospitalisation) and SARS-CoV-2 infection/adverse outcomes from COVID-19 (potentially 
exacerbated by smoking)44. 
 
Limitations 
 
This living rapid evidence review was limited by having a single reviewer extracting data with a 
second independently verifying the data extracted to minimise errors, restricting the search to one 
electronic database and one pre-print server and by not including at least three large population 
surveys due to their reliance on self-reported suspected or confirmed SARS-CoV-2 infection (which 
means they do not meet our eligibility criteria)35,45,46. We also did not include a large, UK-based, 
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representative seroprevalence study47 in our meta-analyses as the odds of testing positive in former 
smokers was not reported. However, the odds of infection for current smokers (OR = 0.64, 95% CI = 
0.58-0.71) was in concordance with the pooled estimate in our meta-analysis. Population surveys – 
particularly with linked data on confirmed infection or antibodies – will be included in future review 
versions to help mitigate some of the limitations of healthcare based observational studies. The 
comparisons of current and former smoking prevalence in the included studies with national 
prevalence estimates did not adjust observed prevalence for the demographic profile of those 
tested/admitted to hospital. Other reviews focused on this comparison have applied adjustments for 
sex and age, and continue to find lower than expected prevalence – notwithstanding the issues 
complicating interpretation described above17. 
 
Implications for research, policy and practice 
 
Further scientific research is needed to resolve the mixed findings summarised in our review. First, 
clinical trials of the posited therapeutic effect of nicotine could have important implications both for 
smokers and for improved understanding of how the SARS-CoV-2 virus causes disease in humans. 
Such trials should focus on medicinal nicotine (as smoked tobacco is a dirty delivery mechanism that 
could mask beneficial effects) and potentially differentiate between different modes of delivery (i.e. 
inhaled vs. ingested) since this can affect pharmacokinetics48 and potential therapeutic effects. A 
second research priority would be a large, representative (randomly sampled) population survey 
with a validated assessment of smoking status which distinguishes between recent and long-term 
ex-smokers – ideally biochemically verified – and assesses seroprevalence and links to health 
records. 
  
In the meantime, public-facing messages about the possible protective effect of smoking or nicotine 
are premature. In our view, until there is further research, the quality of the evidence does not 
justify the huge risk associated with a message likely to reach millions of people that a lethal activity, 
such as smoking, may protect against COVID-19. It continues to be appropriate to recommend 
smoking cessation and emphasise the role of alternative nicotine products to support smokers to 
stop as part of public health efforts during COVID-19. At the very least, smoking cessation reduces 
acute risks from cardiovascular disease and could reduce demands on the healthcare system49. GPs 
and other healthcare providers can play a crucial role – brief, high-quality and free online training is 
available at National Centre for Smoking Cessation and Training. 
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Conclusion 
 
Across 234 studies, recorded smoking prevalence was generally lower than national prevalence 
estimates. Current smokers were at reduced risk of testing positive for SARS-CoV-2 and former 
smokers were at increased risk of hospitalisation, disease severity and mortality compared with 
never smokers. 
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03 
M
ultiple 
821 
Com
m
unity 
      40 
(33-50) 
51.6 
3.3 
- 
- 
- 
- 
96.71 
poor 
139 
Kuderer 
2020-05-
28 
M
ultiple 
928 
Com
m
unity 
and Hospital 
      66 
(57-76) 
50.0 
4.6 
35.1 
- 
50.5 
- 
 9.70 
fair 
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140 
Rom
ao 
2020-06-
08 
Portugal 
34 
Com
m
unity 
     41^ 
(26-66) 
67.7 
- 
- 
26.5 
- 
- 
73.53 
poor 
141 
G
iannouchos 
2020-06-
07 
M
exico 
236,439 
Com
m
unity 
and Hospital 
   42.5^ 
(25-59) 
49.1 
9.1 
- 
- 
- 
90.9 
 0.00 
poor 
142 
Ram
lall 
2020-06-
06 
U
SA 
11,116 
Com
m
unity 
and Hospital 
  52 
(34.7-
69.5) 
55.2 
- 
- 
26.8 
73.2 
- 
 0.00 
poor 
143 
W
ang, O
ekelen 
2020-06-
05 
U
SA 
58 
Com
m
unity 
and Hospital 
         67 
(N
A) 
48.0 
- 
- 
36.2 
- 
- 
63.79 
poor 
144 
Perrone 
2020-06-
05 
Italy 
1,189 
H
ospital 
              
N
A 
21.2 
- 
- 
21.9 
- 
- 
78.13 
poor 
145 
Sharm
a 
2020-06-
05 
India 
501 
H
ospital 
   35.1^ 
(18-51) 
36.0 
- 
- 
4.2 
- 
- 
95.81 
poor 
146 
Eugen-O
lsen 
2020-06-
02 
D
enm
ark 
407 
H
ospital 
      64 
(47-77) 
57.7 
20.6 
36.9 
- 
39.6 
- 
 2.95 
fair 
147 
M
artinez-Portilla 
2020-06-
02 
M
exico 
224 
Com
m
unity 
and Hospital 
      29 
(26-33) 
100.0 
- 
- 
3.1 
- 
- 
96.88 
poor 
148 
Raisi-Estabragh 
2020-06-
02 
U
K 
4,510 
H
ospital 
              
N
A 
48.8 
- 
- 
51.8 
- 
- 
48.20 
poor 
149 
Luo 
2020-06-
02 
China 
625 
H
ospital 
         46 
(N
A) 
47.7 
3.0 
- 
- 
- 
- 
96.96 
poor 
150 
H
oulihan 
2020-06-
09 
U
K 
200 
Com
m
unity 
      34 
(29-44) 
61.0 
11.0 
16.5 
- 
66.5 
- 
 6.00 
fair 
151 
Cen 
2020-06-
08 
China 
1,007 
H
ospital 
      61 
(49-68) 
51.0 
- 
- 
8.7 
- 
- 
91.26 
poor 
152 
Klang 
2020-05-
23 
U
SA 
3,406 
H
ospital 
              
N
A 
61.8 
- 
- 
23.3 
- 
- 
76.72 
poor 
153 
M
araschini 
2020-06-
12 
Italy 
146 
H
ospital 
   32.5^ 
(27-38) 
100.0 
- 
9.6 
- 
80.8 
- 
 9.59 
poor 
154 
W
ang, Zhong 
2020-06-
12 
U
SA 
7,592 
Com
m
unity 
and Hospital 
              
N
A 
45.1 
3.6 
17.1 
- 
51.9 
- 
27.42 
poor 
155 
M
cQ
ueenie 
2020-06-
12 
U
K 
428,199 
Com
m
unity 
and Hospital 
              
N
A 
54.9 
- 
- 
44.4 
55.0 
- 
 0.59 
poor 
26 
M
iyara 
2020-06-
12 
France 
479 
Com
m
unity 
and Hospital 
              
N
A 
44.7 
6.7 
31.6 
- 
59.5 
- 
 1.87 
fair 
156 
Apea 
2020-06-
12 
U
K 
1,737 
H
ospital 
      63.4^ 
(N
A) 
30.4 
- 
- 
10.0 
- 
- 
90.04 
poor 
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157 
W
oolford 
2020-06-
11 
U
K 
4,510 
Com
m
unity 
and Hospital 
       70.5 
(N
A) 
51.2 
13.0 
38.1 
- 
48.1 
- 
 0.80 
fair 
158 
H
ultcrantz 
2020-06-
11 
U
SA 
127 
Com
m
unity 
and Hospital 
      68 
(41-91) 
46.0 
- 
- 
26.8 
72.4 
- 
 0.79 
poor 
159 
Rajter 
2020-06-
10 
U
SA 
280 
H
ospital 
   59.6^ 
(41-77) 
45.5 
5.7 
10.7 
- 
74.6 
- 
 8.93 
fair 
160 
Lan 
2020-06-
09 
U
SA 
104 
Com
m
unity 
     49^ 
(34-63) 
47.1 
- 
- 
24.0 
- 
- 
75.96 
poor 
161 
Zeng 
2020-06-
16 
China 
1,031 
H
ospital 
   60.3^ 
(46-74) 
47.8 
- 
- 
10.2 
- 
- 
89.82 
poor 
162 
Suleym
an 
2020-06-
16 
U
SA 
463 
H
ospital 
   57.5^ 
(40-74) 
55.9 
- 
- 
34.6 
- 
- 
65.44 
poor 
163 
Chen, Yu 
2020-06-
16 
China 
1,859 
H
ospital 
      59 
(45-68) 
50.0 
2.4 
3.6 
- 
94.0 
- 
 0.00 
fair 
164 
G
arassino 
2020-06-
12 
M
ultiple 
200 
Com
m
unity 
and Hospital 
    68 
(61.8-75) 
30.0 
24.0 
55.5 
- 
18.5 
- 
 2.00 
fair 
165 
H
ernandez-
G
arduno 
2020-06-
11 
M
exico 
32,583 
Com
m
unity 
and Hospital 
      45 
(34-56) 
48.7 
- 
- 
11.0 
- 
88.8 
 0.15 
poor 
166 
G
ovind 
2020-06-
20 
U
K 
6,309 
Com
m
unity 
and Hospital 
   46.5^ 
(31-61) 
38.3 
66.3 
26.8 
- 
5.5 
- 
 1.49 
fair 
167 
Siso-Alm
irall 
2020-06-
20 
Spain 
322 
Com
m
unity 
and Hospital 
   56.7^ 
(38-74) 
50.0 
- 
- 
25.2 
- 
- 
74.84 
poor 
168 
G
u 
2020-06-
18 
U
SA 
5,698 
Com
m
unity 
and Hospital 
     47^ 
(26-67) 
62.0 
7.0 
24.7 
- 
50.8 
- 
17.53 
fair 
169 
Kibler 
2020-06-
16 
France 
702 
Com
m
unity 
and Hospital 
     82^ 
(75-88) 
56.0 
3.7 
- 
- 
- 
- 
96.30 
poor 
170 
Ikitim
ur 
2020-06-
03 
Turkey 
81 
H
ospital 
     55^ 
(38-72) 
44.0 
- 
- 
28.4 
- 
- 
71.60 
poor 
171 
Sierpinski 
2020-06-
03 
Poland 
1,942 
Com
m
unity 
         50 
(N
A) 
60.0 
6.3 
- 
- 
- 
49.7 
44.03 
poor 
172 
Zhou, He 
2020-06-
10 
China 
238 
H
ospital 
    55.5 
(35-67) 
57.0 
2.9 
- 
- 
- 
- 
97.06 
poor 
173 
Crovetto 
2020-06-
19 
Spain 
874 
Com
m
unity 
and Hospital 
   33.7^ 
(28-38) 
100.0 
1.1 
- 
- 
- 
13.2 
85.70 
poor 
174 
Veras 
2020-06-
09 
Brazil 
32 
H
ospital 
   58.9^ 
(40-77) 
47.0 
- 
- 
25.0 
- 
- 
75.00 
poor 
175 
Sterlin 
2020-06-
11 
France 
135 
H
ospital 
      61 
(50-72) 
41.0 
3.7 
38.5 
- 
57.8 
- 
 0.00 
fair 
 
This article is protected by copyright. A
ll rights reserved. 
176 
Rossi 
2020-06-
09 
France 
246 
H
ospital 
     68^ 
(53-83) 
39.0 
- 
- 
25.2 
- 
- 
74.80 
poor 
177 
D
uan 
2020-06-
22 
China 
616 
H
ospital 
      64 
(53-70) 
57.5 
3.7 
- 
- 
- 
- 
96.27 
poor 
178 
M
artin-Jim
enez 
2020-06-
09 
Spain 
339 
H
ospital 
    81.6 
(72-87) 
39.5 
- 
- 
30.7 
- 
- 
69.32 
poor 
179 
Elezkurtaj 
2020-06-
17 
G
erm
any 
26 
H
ospital 
  70 
(61.8-
78.3) 
34.6 
- 
- 
19.2 
- 
- 
80.77 
poor 
180 
Lenka 
2020-06-
22 
U
SA 
32 
H
ospital 
   62.2^ 
(51-73) 
37.5 
- 
- 
50.0 
- 
- 
50.00 
poor 
181 
O
livares 
2020-06-
16 
Chile 
21 
H
ospital 
     61^ 
(26-85) 
76.2 
- 
- 
9.5 
- 
- 
90.48 
poor 
182 
Salton 
2020-06-
20 
Italy 
173 
H
ospital 
      64.4^ 
(N
A) 
34.9 
- 
- 
29.5 
- 
- 
70.52 
poor 
183 
W
ei 
2020-06-
18 
U
SA 
147 
H
ospital 
     52^ 
(34-70) 
41.0 
14.3 
- 
- 
- 
- 
85.71 
poor 
184 
Zuo, Estes 
2020-06-
17 
China 
172 
H
ospital 
     61^ 
(25-95) 
44.0 
- 
- 
26.2 
- 
- 
73.84 
poor 
185 
Killerby 
2020-06-
17 
U
SA 
531 
Com
m
unity 
and Hospital 
    51.6 
(38-62) 
57.1 
- 
- 
17.1 
71.4 
- 
11.49 
poor 
186 
Petrilli 
2020-05-
22 
U
SA 
5,279 
Com
m
unity 
and Hospital 
      54 
(38-66) 
51.5 
5.5 
17.1 
- 
61.9 
- 
15.55 
fair 
187 
M
agagnoli 
2020-06-
05 
U
SA 
807 
H
ospital 
      70 
(60-75) 
4.3 
- 
- 
15.9 
- 
- 
84.14 
poor 
33 
N
iedzw
iedz 
2020-05-
29 
U
K 
392,116 
Com
m
unity 
and Hospital 
              
N
A 
54.9 
9.8 
34.8 
- 
55.4 
- 
 0.00 
fair 
188 
Bello-Chavolla 
2020-05-
31 
M
exico 
177,133 
Com
m
unity 
and Hospital 
    42.6 
(26-59) 
48.9 
- 
- 
9.3 
- 
- 
90.72 
poor 
189 
Zuo, Yalavarthi 
2020-04-
24 
U
SA 
50 
H
ospital 
      61 
(46-76) 
34.0 
- 
- 
36.0 
- 
- 
64.00 
poor 
190 
Sigel 
2020-06-
28 
U
SA 
493 
H
ospital 
      60 
(55-67) 
24.1 
- 
- 
28.6 
- 
- 
71.40 
poor 
191 
N
guyen 
2020-06-
29 
U
SA 
689 
Com
m
unity 
and Hospital 
      55 
(40-68) 
57.0 
- 
- 
24.8 
- 
- 
75.18 
poor 
192 
de M
elo 
2020-06-
29 
Brazil 
181 
H
ospital 
   55.3^ 
(34-76) 
60.8 
9.9 
12.2 
- 
38.1 
- 
39.78 
poor 
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193 
Auvinen 
2020-06-
29 
Finland 
61 
H
ospital 
      53 
(41-67) 
36.0 
18.0 
27.9 
- 
54.1 
- 
 0.00 
fair 
194 
Souza 
2020-06-
28 
Brazil 
8,443 
H
ospital 
              
N
A 
53.0 
- 
- 
1.7 
- 
96.3 
 2.01 
poor 
195 
M
endy 
2020-06-
27 
U
SA 
689 
Com
m
unity 
and Hospital 
49.5 
(35.2-
67.5) 
47.0 
- 
- 
24.7 
- 
- 
75.33 
poor 
196 
Pongpirul 
2020-06-
26 
Thailand 
193 
H
ospital 
      37 
(29-53) 
41.5 
- 
- 
15.0 
66.3 
- 
18.65 
poor 
197 
Jin, G
u 
2020-06-
25 
China 
6 
H
ospital 
   60.5^ 
(51-75) 
33.3 
33.3 
- 
- 
- 
- 
66.67 
poor 
198 
Favara 
2020-05-
23 
U
K 
70 
Com
m
unity 
and H
ospital 
      41 
(23-64) 
87.1 
10.0 
- 
- 
- 
- 
90.00 
poor 
199 
Fism
an 
2020-06-
23 
Canada 
21,922 
Com
m
unity 
and Hospital 
              
N
A 
57.0 
- 
- 
2.3 
- 
- 
97.65 
poor 
200 
M
adariaga 
2020-06-
23 
U
SA 
103 
Com
m
unity 
and Hospital 
   41.8^ 
(27-55) 
48.5 
- 
- 
25.2 
74.8 
- 
 0.00 
poor 
201 
Senkal 
2020-07-
07 
Turkey 
611 
H
ospital 
     57^ 
(18-98) 
40.6 
11.3 
- 
- 
- 
- 
88.71 
poor 
202 
M
oham
ud 
2020-07-
02 
U
SA 
6 
H
ospital 
   65.8^ 
(55-78) 
16.7 
- 
- 
16.7 
- 
- 
83.33 
poor 
203 
M
agleby 
2020-06-
30 
U
SA 
678 
H
ospital 
      68 
(50-81) 
38.9 
- 
- 
28.6 
- 
- 
71.39 
poor 
204 
Kim
m
ig 
2020-07-
06 
U
SA 
111 
H
ospital 
     63^ 
(48-78) 
44.1 
7.2 
36.0 
- 
56.8 
- 
 0.00 
fair 
205 
Bello-Chavolla, 
Antonio-Villa 
2020-07-
04 
M
exico 
60,121 
Com
m
unity 
and Hospital 
   45.5^ 
(29-61) 
47.0 
- 
- 
10.5 
- 
- 
89.52 
poor 
206 
Zacharioudakis 
2020-07-
04 
U
SA 
314 
H
ospital 
      64 
(54-72) 
34.7 
- 
- 
22.8 
- 
- 
77.22 
poor 
207 
Antonio-Villa 
2020-07-
04 
M
exico 
34,263 
Com
m
unity 
and Hospital 
     40^ 
(29-50) 
62.9 
9.7 
- 
- 
- 
- 
90.32 
poor 
208 
Patel 
2020-07-
03 
U
SA 
129 
H
ospital 
   60.8^ 
(47-74) 
45.0 
37.2 
- 
- 
- 
55.8 
 6.98 
poor 
209 
M
erzon 
2020-07-
03 
Israel 
7,807 
Com
m
unity 
and Hospital 
      46.2^ 
(N
A) 
58.6 
- 
- 
16.2 
- 
- 
83.82 
poor 
34 
Trubiano 
2020-07-
02 
Australia 
2,935 
Com
m
unity 
and Hospital 
      39 
(29-53) 
63.5 
- 
- 
8.8 
- 
- 
91.18 
poor 
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210 
Fan 
2020-07-
11 
U
K 
1,425 
Com
m
unity 
and Hospital 
              
N
A 
46.7 
12.2 
40.1 
- 
46.9 
- 
 0.84 
fair 
211 
Shi, Resurreccion 
2020-07-
11 
U
K 
1,521 
Com
m
unity 
and Hospital 
 61.5^ 
(57-66.8) 
45.9 
- 
- 
54.9 
- 
- 
45.10 
poor 
212 
M
aucourant 
2020-07-
10 
Sw
eden 
27 
H
ospital 
      57 
(18-78) 
22.2 
11.1 
25.9 
- 
40.7 
- 
22.22 
poor 
213 
Elm
unzer 
2020-07-
09 
M
ultiple 
1,992 
H
ospital 
     60^ 
(43-76) 
43.0 
6.3 
28.6 
- 
59.0 
- 
 6.12 
fair 
214 
Alizadehsani 
2020-07-
09 
Iran 
319 
H
ospital 
  45.48^ 
(26-63) 
55.5 
- 
- 
0.3 
- 
- 
99.69 
poor 
215 
Xie 
2020-07-
07 
China 
619 
H
ospital 
              
N
A 
52.0 
- 
- 
8.2 
- 
- 
91.76 
poor 
36 
M
erkely 
2020-07-
17 
H
ungary 
10,474 
Com
m
unity 
   48.7^ 
(30-66) 
53.6 
28.0 
20.5 
- 
51.4 
- 
 0.16 
good 
216 
Fox 
2020-07-
17 
U
K 
55 
Com
m
unity 
and Hospital 
      63 
(23-88) 
31.0 
1.8 
10.9 
- 
56.4 
- 
30.91 
poor 
56 
Zhang, Cao 
2020-07-
14 
China 
289 
H
ospital 
      57 
(22-88) 
46.6 
3.5 
6.2 
- 
- 
- 
90.31 
poor 
217 
M
artinez--
Resendez 
2020-07-
20 
M
exico 
8 
H
ospital 
      57 
(48-69) 
25.0 
- 
- 
12.5 
- 
- 
87.50 
poor 
218 
H
oertel 
2020-07-
20 
France 
12,612 
H
ospital 
   58.7^ 
(39-77) 
49.6 
- 
- 
9.3 
- 
- 
90.72 
poor 
219 
M
cgrail 
2020-07-
19 
U
SA 
209 
H
ospital 
       62.5 
(N
A) 
38.8 
- 
- 
18.7 
- 
- 
81.34 
poor 
220 
Pandolfi 
2020-07-
17 
Italy 
33 
H
ospital 
      62 
(52-65) 
21.1 
3.0 
24.2 
- 
72.7 
- 
 0.00 
fair 
28 
G
irardeau 
2020-07-
17 
France 
10 
Com
m
unity 
      30 
(29-33) 
50.0 
40.0 
10.0 
- 
- 
- 
40.00 
poor 
221 
Kurashim
a 
2020-07-
17 
Japan 
53 
H
ospital 
   62.9^ 
(49-76) 
35.8 
- 
- 
50.9 
- 
- 
49.06 
poor 
222 
Zhan 
2020-07-
16 
China 
75 
H
ospital 
      57 
(25-75) 
48.0 
- 
- 
12.0 
- 
- 
88.00 
poor 
223 
O
m
rani 
2020-07-
16 
Q
atar 
1,409 
Com
m
unity 
and H
ospital 
      39 
(30-50) 
17.2 
- 
- 
9.2 
- 
- 
90.77 
poor 
224 
G
upta 
2020-07-
16 
U
SA 
496 
H
ospital 
      70 
(60-78) 
46.0 
- 
- 
7.3 
- 
31.7 
61.09 
poor 
225 
Shi, Zuo 
2020-07-
15 
U
SA 
172 
H
ospital 
  61.48^ 
(25-96) 
44.0 
- 
- 
26.2 
- 
- 
73.84 
poor 
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226 
H
ussein 
2020-07-
15 
U
SA 
502 
H
ospital 
   60.9^ 
(45-76) 
52.0 
9.0 
22.1 
- 
- 
68.9 
 0.00 
poor 
227 
Bian 
2020-07-
15 
China 
28 
H
ospital 
     56^ 
(42-67) 
42.9 
7.1 
- 
- 
- 
- 
92.86 
poor 
228 
Eiros 
2020-07-
14 
Spain 
139 
Com
m
unity 
and Hospital 
      52 
(41-57) 
72.0 
4.3 
50.4 
- 
- 
- 
45.32 
poor 
229 
M
arcos 
2020-07-
14 
Spain 
918 
H
ospital 
   72.8^ 
(58-87) 
42.2 
6.1 
- 
15.3 
- 
- 
78.65 
poor 
230 
H
oertel, Sanchez-
Rico 
2020-07-
14 
France 
7,345 
H
ospital 
              
N
A 
49.3 
8.5 
- 
- 
- 
- 
91.52 
poor 
231 
Soares 
2020-07-
16 
Brazil 
10,713 
Com
m
unity 
and Hospital 
              
N
A 
55.0 
2.0 
- 
- 
- 
98.0 
 0.00 
poor 
232 
Zobairy 
2020-07-
28 
Iran 
203 
Com
m
unity 
and Hospital 
   49.2^ 
(32-65) 
44.8 
5.9 
- 
- 
- 
94.1 
 0.00 
poor 
233 
Altam
im
i 
2020-07-
27 
Q
atar 
68 
H
ospital 
     49^ 
(40-58) 
2.0 
16.4 
- 
- 
- 
83.6 
 0.00 
poor 
234 
Thom
pson 
2020-07-
27 
U
K 
470 
H
ospital 
      71 
(57-82) 
46.0 
14.0 
27.2 
- 
58.7 
- 
 0.00 
fair 
235 
Reiter 
2020-07-
26 
Austria 
235 
Com
m
unity 
   44.2^ 
(32-55) 
70.0 
22.6 
22.6 
- 
54.7 
- 
 0.00 
fair 
236 
M
otta 
2020-07-
26 
U
SA 
374 
H
ospital 
   64.7^ 
(46-82) 
41.4 
- 
- 
33.2 
66.8 
- 
 0.00 
poor 
237 
Santos 
2020-07-
25 
U
SA 
43 
Com
m
unity 
and Hospital 
      50 
(34-73) 
63.0 
- 
- 
4.7 
- 
- 
95.35 
poor 
238 
Schneew
eiss 
2020-07-
22 
U
SA 
24,313 
Com
m
unity 
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     67^ 
(53-80) 
53.0 
- 
- 
2.9 
- 
- 
97.12 
poor 
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2020-07-
24 
Colom
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72 
Com
m
unity 
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      46 
(28-64) 
47.0 
8.3 
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- 
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80.56 
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2020-07-
24 
Spain 
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Com
m
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     42^ 
(18-66) 
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- 
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- 
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2020-07-
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38.5 
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- 
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6.9 
17.2 
- 
- 
- 
82.8 
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N
ote. – Age not provided for total sam
ple; ^ Denotes m
ean (SD). * This study w
as rated as ‘poor’ quality as the m
anuscript only presents data for current 
(but not form
er) sm
okers despite having obtained com
plete sm
oking status, thus resulting in >20%
 m
issing data on sm
oking status. 
Table 1. Characteristics of included studies. 
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24.5 
- 
- 
- 
- 
75.54 
poor 
266 
Zhao, Chen 
2020-07-
30 
U
SA 
641 
H
ospital 
         60 
(N
A) 
40.1 
21.7 
- 
- 
- 
- 
78.32 
poor 
267 
H
olm
an 
2020-08-
13 
U
K 
10,989 
Com
m
unity 
and Hospital 
              
N
A 
38.8 
5.5 
42.6 
- 
49.0 
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Figure 2a. Weighted mean prevalence of current smoking in included studies with 95% bootstrap 
confidence intervals compared with national current smoking prevalence (solid red lines), split by 
country. Shape corresponds to study setting (community, community and hospital, hospital) and 
shape size corresponds to relative study sample size. 
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Figure 2b. Weighted mean prevalence of former smoking in included studies (where this was 
reported) with 95% bootstrap confidence intervals compared with national former smoking 
prevalence (solid red lines), split by country. Shape corresponds to study setting (community, 
community and hospital, hospital) and shape size corresponds to relative study sample size. 
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(52.92%
) 
- 
924 
(33.72%
) 
- 
551 
(16.74%
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(11.04%
) 
525 
(39.98%
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N
ote. N
iedzw
iedz et al. reported on SARS-CoV-2 infection by sm
oking status in m
ultivariable analyses but did not present raw
 data.  
 Table 2. SARS-CoV-2 infection by sm
oking status. 
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Figure 3. Forest plot for risk of testing positive for SARS-CoV-2 in current vs. never smokers. * This 
was a ‘good’ quality study. 
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Figure 4. Forest plot for risk of testing positive for SARS-CoV-2 in former vs. never smokers. 
* This was a ‘good’ quality study.
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Figure 5. Forest plot for risk of hospitalisation in current vs. never smokers. 
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Figure 6. Forest plot for risk of hospitalisation in former vs. never smokers.
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 Table 4. Disease severity by sm
oking status. 
D
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1381 
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(44%
) 
- 
- 
239 (38.61%
) 
292 
(47.17%
) 
- 
88 
(14.22%
) 
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(55%
) 
- 
- 
338 (44.36%
) 
304 
(39.90%
) 
- 
120 
(15.75%
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) 
- 
Zhou, Sun 
144 
108 
(75%
) 
11 
(10.19%
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(89.81%
) 
36 
(25%
) 
2 (5.56%
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(62%
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(21.86%
) 
- 
- 
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(78.14%
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(30%
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(26.67%
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(73.33%
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(91%
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(39.82%
) 
- 
- 
- 
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(60.18%
) 
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(8%
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(70.00%
) 
- 
- 
- 
- 
6 (30.00%
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Figure 7. Forest plot for the risk of severe disease in current vs. never smokers. 
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Figure 8. Forest plot for the risk of severe disease in former vs. never smokers.
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eng 
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) 
- 
- 
175 
(87.50%
) 
G
aribaldi 
747 
634 
(84%
) 
36 
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ote. Solis et al. and the O
penSAFELY Collaborative reported on m
ortality by sm
oking status in a m
ultivariable  
analysis but did not present raw
 data for both the exposure and outcom
e variables. 
 Table 5. M
ortality by sm
oking status. 
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Figure 9. Forest plot for the risk of mortality in current vs. never smokers. 
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Figure 10. Forest plot for the risk of mortality in former vs. never smokers. 
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Figure 11. A schematic of some of the interpretation issues for the association of smoking and SARS-
CoV-2/COVID-19. * Indicates potential confounding with smoking status. 
 
 
